Cargando…
Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?
The pandemic of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a significant threat to global health. Currently, no specific prophylactic and therapeutic treatment is available. No evidence from randomized clinical trials (RCTs) that a treatment may ameliorate...
Autores principales: | Dalamaga, Maria, Karampela, Irene, Mantzoros, Christos S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207125/ https://www.ncbi.nlm.nih.gov/pubmed/32418885 http://dx.doi.org/10.1016/j.metabol.2020.154260 |
Ejemplares similares
-
Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?
por: Karampela, Irene, et al.
Publicado: (2020) -
Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19
por: Dalamaga, Maria, et al.
Publicado: (2020) -
Can iron chelation as an adjunct treatment of COVID-19 improve the clinical outcome?
por: Abobaker, Anis
Publicado: (2020) -
Does COVID-19 Involve the Retina?
por: Karampelas, Michael, et al.
Publicado: (2020) -
The combination of bromelain and curcumin as an immune-boosting nutraceutical in the prevention of severe COVID-19
por: Kritis, Panagiotis, et al.
Publicado: (2020)